Atlanta Consulting Group Advisors LLC Acquires New Position in AstraZeneca PLC (NASDAQ:AZN)

Atlanta Consulting Group Advisors LLC bought a new position in shares of AstraZeneca PLC (NASDAQ:AZN) during the third quarter, HoldingsChannel reports. The firm bought 2,618 shares of the company’s stock, valued at approximately $204,000.

Other hedge funds also recently made changes to their positions in the company. McClarren Financial Advisors Inc. lifted its stake in AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after purchasing an additional 247 shares during the last quarter. GHP Investment Advisors Inc. acquired a new stake in shares of AstraZeneca during the second quarter worth $26,000. Capital Performance Advisors LLP bought a new position in shares of AstraZeneca in the 3rd quarter worth about $28,000. Pathway Financial Advisers LLC acquired a new position in shares of AstraZeneca in the 1st quarter valued at about $29,000. Finally, Hobbs Group Advisors LLC bought a new stake in shares of AstraZeneca during the 2nd quarter valued at about $35,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

AZN has been the topic of a number of recent research reports. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Erste Group Bank upgraded AstraZeneca from a “hold” rating to a “buy” rating in a research report on Wednesday, September 11th. Finally, TD Cowen upped their price objective on AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, AstraZeneca presently has an average rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Stock Performance

Shares of NASDAQ AZN opened at $63.23 on Monday. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68. The company has a current ratio of 0.93, a quick ratio of 0.71 and a debt-to-equity ratio of 0.71. The company has a market cap of $196.05 billion, a PE ratio of 30.25, a P/E/G ratio of 1.17 and a beta of 0.47. The stock has a 50 day simple moving average of $75.03 and a 200-day simple moving average of $78.23.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The company had revenue of $13.57 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same quarter in the prior year, the business posted $0.87 earnings per share. The company’s revenue for the quarter was up 18.0% compared to the same quarter last year. On average, equities research analysts forecast that AstraZeneca PLC will post 4.07 EPS for the current year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.